Opko Health (OPK) : Menora Mivtachim Holdings Ltd. scooped up 300,000 additional shares in Opko Health during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 3,339,693 shares of Opko Health which is valued at $34,666,013.Opko Health makes up approximately 1.85% of Menora Mivtachim Holdings Ltd.’s portfolio.
Other Hedge Funds, Including , Cubist Systematic Strategies reduced its stake in OPK by selling 7,400 shares or 36.06% in the most recent quarter. The Hedge Fund company now holds 13,121 shares of OPK which is valued at $136,196. Opko Health makes up approx 0.01% of Cubist Systematic Strategies’s portfolio. Nbw Capital sold out all of its stake in OPK during the most recent quarter. The investment firm sold 11,603 shares of OPK which is valued $112,897. World Asset Management Inc added OPK to its portfolio by purchasing 13,817 company shares during the most recent quarter which is valued at $130,156.First Manhattan Co boosted its stake in OPK in the latest quarter, The investment management firm added 6,000 additional shares and now holds a total of 20,000 shares of Opko Health which is valued at $185,800.
Opko Health opened for trading at $10.5 and hit $10.69 on the upside on Monday, eventually ending the session at $10.48, with a gain of 0.19% or 0.02 points. The heightened volatility saw the trading volume jump to 29,09,567 shares. Company has a market cap of $5,843 M.
On the company’s financial health, Opko Health reported $-0.03 EPS for the quarter, based on the information available during the earnings call on Nov 7, 2016. Analyst had a consensus estimate of $-0.03. The company had revenue of $298.00 million for the quarter, compared to analysts expectations of $322.03 million. The company’s revenue was up 108.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.25 EPS.
OPKO Health Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose treat and prevent various conditions including point-of-care tests laboratory developed tests (LDTs) molecular diagnostics tests and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile Spain Mexico Israel Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.